LHRH Agonist

Phase 3Small molecule

Roche

LHRH Agonist is one of 83 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Locally Advanced or Metastatic Breast CancerActive, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerActive, not recruiting

Breast CancerActive, not recruiting

ProstatectomyActive, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Locally Advanced or Metastatic Breast CancerPhase 3

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

ProstatectomyPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

LHRH Agonist

Roche

Phase 3

9 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Breast Cancer

NCT03879577

Q4 2026

Phase 3Active, not recruiting

Breast Cancer

NCT05306340

Phase 2Active, not recruiting

Prostate Cancer

NCT05498272

Q1 2027

Phase 2Active, not recruiting

Breast Cancer

NCT06001762

Q3 2027

Phase 3Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

NCT04546009

Phase 1Active, not recruiting

Breast Cancer

NCT03332797

Clinical

Trials by Indication[1]

Prostate Cancer10 trials

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00288080·612 enrolled

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006359·63 enrolled

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00430183·788 enrolled

Show 7 more trials

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

Completed·RRabin Medical Center·Phase 4·NCT02475057·80 enrolled

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00528866·80 enrolled

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00005044·1,579 enrolled

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00567580·1,792 enrolled

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

Completed· Ferring logo

Ferring··NCT02234089·461 enrolled

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Completed·AAragon Pharmaceuticals, Inc.·Phase 2·NCT01790126·90 enrolled

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)

Active, not recruiting·RRana McKay, MD·Phase 2·NCT05498272·32 enrolled

Breast Cancer9 trials

FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer

Active, not recruiting·FFondazione Sandro Pitigliani·Phase 2·NCT03944434·116 enrolled

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04961996·4,170 enrolled

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Recruiting·FFudan University·Phase 3·NCT05891093·766 enrolled

Show 6 more trials

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT03879577·53 enrolled

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Terminated· Roche logo

Roche·Phase 1/2·NCT01823835·152 enrolled

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05306340·373 enrolled

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Withdrawn·UUniversity of Chicago·Phase 2·NCT03058939

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 1·NCT03332797·181 enrolled

The TRADE Study: A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose Escalation in Patients With Early-Stage HR-positive and HER2-negative Breast Cancer

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT06001762·90 enrolled

Prostatectomy2 trials

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00329043·64 enrolled

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01674270·35 enrolled

Locally Advanced or Metastatic Breast Cancer2 trials

A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04576455·303 enrolled

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05296798·922 enrolled

Prostate1 trial

Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

Unknown status·JJuravinski Cancer Center·Phase 2·NCT03380806·100 enrolled

2 more indications

Advanced Breast Cancer1 trial

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT06065748·1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1 trial

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04546009·992 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for LHRH Agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LHRH Agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LHRH Agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

LHRH Agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Prostate Cancer10 trials

Breast Cancer9 trials

Prostatectomy2 trials

Locally Advanced or Metastatic Breast Cancer2 trials

Prostate1 trial

Advanced Breast Cancer1 trial

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News